Scientific Program

Conference Series Ltd invites all the participants across the globe to attend Vitiligo and Skincare Physicians Meetings Berlin, Germany.

Day 2 :

Keynote Forum

Agustin Alomar Muntañola

University of Barcelona, Spain

Keynote: How to face vitiligo treatment
OMICS International Vitiligo and Skincare 2016 International Conference Keynote Speaker Agustin Alomar Muntañola photo
Biography:

Agustin Alomar Muntanola is a Dermatologist of University of Barcelona, Barcelona Vice-president and Treasurer in the Organizing Committee of the Congress of EADV, Barcelona, 2003. He is the member of Member of Spanish Academy of Dermatology and Venereology, Ibero-Latino-Americano College of Dermatology, European Society of Dermatological Research, American Academy of Dermatology, European Academy of Dermatology and Venereology, European Society of Contact Dermatitis, American Contact Dermatitis Society. He is Founding member of the Vitiligo European Task Force VETF. He is the President Organizing Committee of the XXIX  National Congress of the Spanish Academy of Dermatology and Venereology, 20-24 June 2001, Barcelona.

Abstract:

When evaluating vitiligo, the dermatologist must bear in mind that although not a serious health risk, it does have a great psychological impact, which is why he must be proactive and be motivated to convince the patient to carry out the treatment. As with any dermatological process which does not guarantee a total cure and with a long-term yet simple treatment perspective which despite being uncomfortable has very rare side effects, the vitiligo-dedicated dermatologist must know how to transmit to the patient the three following virtues: Faith, Hope and Charity: Faith in the doctor, Hope that the treatment can work and Charity with himself to accept the compliance of a hard and prolonged treatment. Personally this is the focus that I use with my patients that usually come to me looking for an expert. My treatment can be prescribed by any dermatologist but it could be difficult to obtain nice results without following the recommendations mentioned previously. What is the basic treatment for me? Taking as a starting point that treatments must suit the patient and not only the illness, I personally manage the following: Topical Tacrolimus: Its use has become fashionable without many dermatologists knowing exactly why. It is not merely an anti-inflammatory, there are studies which explain scientifically that Tacrolimus is able to increase tyrosine activity of the melanocyte and increase its migratory ability. Ultraviolet Light: Mainly in UVB-NB band or even sunlight controlled exposition in sunny countries like Spain. Without light it is impossible to stimulate melanocytes from any reservoir, such as the peri-folicular niche or peri-lesional skin. Topical Khellin: 30 years of experience have convinced me completely about the use of topically applied khellin plus sunlight exposure. Although its capacity to stimulate melanocyte mitosis is inferior to psoralens, its long-term safety is important. Topical application of khellin achieves a notable level of penetration of the active substance to the basal layer in just an hour (recent unpublished research), but also daily application achieves an effective epidermic depot effect. The combination of a minimum daily sunlight exposure of 5, 10 or 15 minutes if possible usually produces excellent results in responsive body areas. Oral Antioxidants: Given that the function of light is essential yet knowing that it stimulates free radical production, using Prof. Schallreuter’s theory of melanocyte defect that they are unable to clean these toxic products, it seems useful to provide oral antioxidants to manage free radicals in vitiligo. Those with proven efficacy such as Polypodium Leucotomos and Vitamin E protect against possible photo-induced damage and create a better environment for new melanocyte migration. It is clear that these options are not the only possible therapies for all vitiligo cases but they are very effective especially in countries where controlled sunlight exposure is cheap and easy for 7 or 8 months a year. Over 30 years dedicated to treating vitiligo patients allow me to share this experience with which I have obtained excellent results.

 

  • Immune mediators and thier role in vitiligo l Theories for Vitiligo pathogenesis l New insights in segmental vitiligo l Surgical management of vitiligo
Location: Sylt 3

Session Introduction

Seyed Mohhamed Radmanesh

Ahvaz Jundishapur University of Medical Sciences, Iran

Title: Generalized vitiligo development in the patients who has used monobenzone for the treatment of melasma
Speaker
Biography:

Seyed Mohammad Radmanesh has completed his Medicine and Dermatologic Residency in Shiraz University of Medical Sciences, Shiraz Iran previously known as Pahlavi University and received the National Board of Dermatology in 1993. From 1993, he is an Academic Member of Ahvaz University of Medical Sciences, Iran. He is currently the Associate Professor of Dermatology. One of the fields of his interest is vitiligo. He has published several papers in the literature, some are the reference papers.

 

Abstract:

The melanocytes of different body areas have different susceptibility for vitiligo involvement. In the case of non-segmental vitiligo, many areas are more prone to develop vitiligo earlier than other sites. The areas that develop vitiligo earlier and are more prone to vitiligo are periorbital, perioral, mucosal genitalia in men and distal extremities and the areas that usually involved by vitiligo later are more resistant to vitiligo are thighs, trunk, particularly the lower trunk and arms. For these reasons the areas that are more resistant to vitiligo are chosen to harvest melanocytes or tissue autograft. Any cell or tissue autograft including the suction blister autograft is performed when the vitiligo is in a stable state. The stable vitiligo is defined as a condition in which there is no extension of the previous lesions and development of no new lesions within the past 6-12 months. For many cases of stable vitiligo we have done suction blister autograft. Years later the disease became flared up in some of those who received suction blister autograft. The vitiligo started to develop from different areas as well as the areas surrounding the grafted areas but surprisingly spared the grafted areas. This finding supports the hypothesis that melanocytes from different areas have different susceptibility to vitiligo.